Our deal team, led by Michel van Agt and Menno Baks, and including Rik Walschot, Jeroen Rijssenbeek and Sjoerd Koster, acting alongside the DORDA team, led by Jürgen Kittel and Christoph Brogyányi, in Austria, is advising Croma-Pharma on this business combination.
Croma-Pharma GmbH signed a Business Combination Agreement with European Healthcare Acquisition & Growth Company B.V.
1 minute read
Croma-Pharma GmbH (”Croma”), an Austrian based fast-growing and internationally leading family-owned business in the fields of minimally invasive aesthetics and reconstructive medicine, will go public on Euronext Amsterdam via a business combination with European Healthcare Acquisition & Growth Company B.V. (“EHC”), a Dutch operators-led special purpose acquisition company. This is the first de-SPAC transaction announced for an Austrian company. Upon closing of the transaction, EHC is expected to be converted and renamed into Croma N.V.
